The Neurofibromatoses Type II drugs in development market research report provides comprehensive information on the therapeutics under development for Neurofibromatoses Type II, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Neurofibromatoses Type II. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Neurofibromatoses Type II and features dormant and discontinued products.
GlobalData tracks eight drugs in development for Neurofibromatoses Type II by eight companies/universities/institutes. The top development phase for Neurofibromatoses Type II is phase ii with five drugs in that stage. The Neurofibromatoses Type II pipeline has eight drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Neurofibromatoses Type II pipeline products market are: Plex Pharmaceuticals, AstraZeneca and OncoTherapy Science.
The key targets in the Neurofibromatoses Type II pipeline products market include Epidermal Growth Factor Receptor (Proto Oncogene c ErbB 1 or Receptor Tyrosine Protein Kinase erbB 1 or HER1 or ERBB1 or EGFR or EC 2.7.10.1), Dual Specificity Mitogen Activated Protein Kinase Kinase 2 (ERK Activator Kinase 2 or MAPK/ERK Kinase 2 or MAP2K2 or EC 2.7.12.2), and Dual Specificity Mitogen Activated Protein Kinase Kinase 1 (ERK Activator Kinase 1 or MAPK/ERK Kinase 1 or MAP2K1 or EC 2.7.12.2).
The key mechanisms of action in the Neurofibromatoses Type II pipeline product include Epidermal Growth Factor Receptor (Proto Oncogene c ErbB 1 or Receptor Tyrosine Protein Kinase erbB 1 or HER1 or ERBB1 or EGFR or EC 2.7.10.1) Inhibitor with two drugs in Phase II. The Neurofibromatoses Type II pipeline products include three routes of administration with the top ROA being Oral and three key molecule types in the Neurofibromatoses Type II pipeline products market including Small Molecule, and Subunit Vaccine.
Neurofibromatoses Type II overview
Neurofibromatosis type 2 is a disorder characterized by the growth of noncancerous tumors in the nervous system. These growths develop along the nerve that carries information from the inner ear to the brain (the auditory nerve). Tumors that occur on other nerves are also commonly found with this condition. The signs and symptom are hearing loss, ringing in the ears (tinnitus), and problems with balance.
For a complete picture of Neurofibromatoses Type II’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
